{"id":2139,"date":"2019-02-11T05:25:41","date_gmt":"2019-02-11T04:25:41","guid":{"rendered":"http:\/\/www.fedecame.com\/?page_id=2139"},"modified":"2019-03-15T07:40:01","modified_gmt":"2019-03-15T06:40:01","slug":"cdr-camesank-sankuru","status":"publish","type":"page","link":"https:\/\/www.fedecame.net\/wp1\/?page_id=2139","title":{"rendered":"CDR CAMESANK-Sankuru"},"content":{"rendered":"<h5><strong>\u00a0I. <\/strong><strong>Identification de la CDR<\/strong><\/h5>\n<ul>\n<li>DATE DE CREATION : 07\/02\/2017<\/li>\n<li>DATE D\u2019ACQUISITION DE LA PERSONNALITE JURIDIQUE : on a jusque-l\u00e0 le F,92<\/li>\n<li>DATE D\u2019AUTORISATION D\u2019OUVERTURE EN TANT QUE DEP\u00d4T PHARMACEUTIQUE : le 01\/03\/2017<\/li>\n<li>DATE DE SIGNATURE CONVENTION ETAT CDR : LE 24 FEVRIER 2017<\/li>\n<li>DATE D\u2019ADOPTION DES STATUTS D\u2019ASBL : LE 29 janvier 2017.<\/li>\n<li>DATE SIGNATURE CONVENTION CDR \u2013 FEDECAME : 2017<\/li>\n<li>POPULATION DESSERVIE : environs 4000000<\/li>\n<li>NOMBRE DE ZONE DE SANTE COUVERTES : 16<\/li>\n<li>NOMBRE DE ZONE DE SANTE SERVIES EFFECTIVEMENT : 16<\/li>\n<li>EFFECTIF DU PERSONNEL : nous disposons de 7 agents cadres et nous faisons recours permanent au personnel d\u2019appoint<\/li>\n<\/ul>\n<h5>II. Activit\u00e9s : bilan 2015 \u00e0 2017 &amp; pr\u00e9visions 2018<\/h5>\n<ol>\n<li><strong>EVOLUTION DES CHIFFRES D\u2019AFFAIRES TROIS DERNIERES ANNEES (Vente Meg et Services)<\/strong>\n<ul>\n<li><strong>2015 Ventes MEG : RAS\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Services : RAS<\/strong><\/li>\n<li><strong>2016 Ventes MEG : RAS\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Services : RAS<\/strong><\/li>\n<li><strong>2017 Ventes MEG : RAS\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Services : 136733,32 USD<\/strong><\/li>\n<li><strong>2018 (pr\u00e9vision) Ventes MEG : \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Services :126417,13 USD pour le 1<sup>e<\/sup> semestre<\/strong><\/li>\n<\/ul>\n<\/li>\n<li><strong>VENTILATION DES VENTES DES MEDICAMENTS PAR GOUPES DES CLIENTS<\/strong>\n<ul>\n<li><strong>Groupe 1 : CA : RAS\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 % :\u00a0 RAS<\/strong><\/li>\n<li><strong>Groupe 2 CA : RAS\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 % :\u00a0 RAS<\/strong><\/li>\n<li><strong>Groupe 3 : CA : RAS\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 % :\u00a0 RAS<\/strong><\/li>\n<li><strong>Groupe 4 : CA : RAS\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 % :\u00a0 RAS<\/strong><\/li>\n<\/ul>\n<\/li>\n<li><strong>EVOLUTION DU FONDS DE ROULEMENT<\/strong>\n<ul>\n<li><strong>2015 Valeur : RAS\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Orientation : RAS<\/strong><\/li>\n<li><strong>2016 Valeur : RAS\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Orientation : RAS<\/strong><\/li>\n<li><strong>2017 Valeur : RAS.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Orientation : RAS.<\/strong><\/li>\n<li><strong>2018 (pr\u00e9vision) Valeur : (100000 USD venus de la DPS comme remont\u00e9 de fonds de roulement) et les produits pharmaceutiques de valeurs de 202000 USD de fonds GAVI en provenance de la FEDECAME\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Orientation : \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.<\/strong><\/li>\n<\/ul>\n<\/li>\n<li><strong>VOLUMES DES ACHATS EFFECTUES AU COURS DE TROIS DERNIERES ANNEES PAR SOURCES (RESEAU ET HORS RESEAU)<\/strong>\n<ul>\n<li><strong>2015 R\u00e9seau et % : RAS\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hors R\u00e9seau et % : RAS<\/strong><\/li>\n<li><strong>2016 R\u00e9seau et % : RAS\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hors R\u00e9seau et % : RAS\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/strong><\/li>\n<li><strong>2017 R\u00e9seau et % : RAS\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hors R\u00e9seau et % : RAS<\/strong><\/li>\n<li><strong>2018 (pr\u00e9visions) R\u00e9seau et 100% :\u00a0 202000 USD Hors R\u00e9seau et % : \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026<\/strong><\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<p><strong>\u00a0<\/strong><\/p>\n<h5><strong>III. Contacts\u00a0: <\/strong><\/h5>\n<p>courriel : <a href=\"mailto:asblcamesank@gmail.com\">asblcamesank@gmail.com<\/a><\/p>\n<p><strong>Directeur Joseph LOKAMANA<br \/>\n<\/strong><\/p>\n<p>T\u00e9l\u00e9phone\u00a0: 0810036784 &#8211; 0975766562<\/p>\n<p>Courriel\u00a0: <a href=\"mailto:josephlokamana@gmail.com\">josephlokamana@gmail.com<\/a><\/p>\n<p><strong>Directeur Adjoint\u00a0 DIKENDE OLUWA<br \/>\n<\/strong><\/p>\n<p>T\u00e9l\u00e9phone\u00a0: 0813055545<\/p>\n<p>Courriel\u00a0: <a href=\"mailto:Dikende.jean@yahoo.com\">Dikende.jean@yahoo.com<\/a><\/p>\n<p><strong>\u00a0<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0I. Identification de la CDR DATE DE CREATION : 07\/02\/2017 DATE D\u2019ACQUISITION DE LA PERSONNALITE JURIDIQUE : on a jusque-l\u00e0 le F,92 DATE D\u2019AUTORISATION D\u2019OUVERTURE EN TANT QUE DEP\u00d4T PHARMACEUTIQUE : le 01\/03\/2017 DATE DE SIGNATURE CONVENTION ETAT CDR : LE 24 FEVRIER 2017 DATE D\u2019ADOPTION DES STATUTS D\u2019ASBL : LE 29 janvier 2017. DATE&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/www.fedecame.net\/wp1\/index.php?rest_route=\/wp\/v2\/pages\/2139"}],"collection":[{"href":"https:\/\/www.fedecame.net\/wp1\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.fedecame.net\/wp1\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedecame.net\/wp1\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedecame.net\/wp1\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2139"}],"version-history":[{"count":1,"href":"https:\/\/www.fedecame.net\/wp1\/index.php?rest_route=\/wp\/v2\/pages\/2139\/revisions"}],"predecessor-version":[{"id":2141,"href":"https:\/\/www.fedecame.net\/wp1\/index.php?rest_route=\/wp\/v2\/pages\/2139\/revisions\/2141"}],"wp:attachment":[{"href":"https:\/\/www.fedecame.net\/wp1\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}